LEXICON PHARMACEUTICALS, INC.

Analyst Reco. Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
1.54 ^USD	-1.28%		-4.35%	+0.65%

30/04	Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	MT
29/04	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	30/04	MT
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	26/03	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	10/23/10	DJ
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating	31/23/31	MT
Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target	07/23/07	MT
Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage	12/22/12	MT
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target	12/22/12	MT
Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating	01/22/01	MT
LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals	11/21/11	MT
LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating	30/21/30	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept	11/21/11	MT
LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7	29/21/29	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2	29/21/29	MT
LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10	08/20/08	MT
LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold	18/20/18	MT
LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating	03/20/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer